title: Clonal deletion with bortezomib followed by low or no maintenance immunosuppression in renal allograft recipients.
authors.forename: Hargovind L
authors.initials: HL
authors.lastname: Trivedi
authors.forename: Paul I
authors.initials: PI
authors.lastname: Terasaki
authors.forename: Aziz
authors.initials: A
authors.lastname: Feroz
authors.forename: Aruna V
authors.initials: AV
authors.lastname: Vanikar
authors.forename: Varsha B
authors.initials: VB
authors.lastname: Trivedi
authors.forename: Sajni I
authors.initials: SI
authors.lastname: Khemchandani
authors.forename: Shruti D
authors.initials: SD
authors.lastname: Dave
authors.forename: Vangipuram
authors.initials: V
authors.lastname: Shankar
authors.forename: Pranjal R
authors.initials: PR
authors.lastname: Modi
authors.forename: Hugo
authors.initials: H
authors.lastname: Kaneku
authors.forename: Adam
authors.initials: A
authors.lastname: Idica
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Everly
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D002648:Child; D017637:Clonal Deletion / Q000276:immunology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology; D007258:Informed Consent; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use*; D014184:Transplantation, Homologous / Q000276:immunology
chemical_list: D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib